Why physical stability is critical for suspensions:

Pharmaceutical suspensions contain dispersed solid particles in a liquid medium. Over time, particles may undergo physical changes such as crystal growth or irreversible aggregation. These changes reduce redispersibility, affect sedimentation behavior, and lead to non-uniform dosing. During stability studies, visual inspection alone is insufficient to detect such transformations. Monitoring crystal size and aggregation behavior is essential to maintaining product efficacy and regulatory compliance.

Consequences of undetected physical changes in suspensions:

Crystal growth or aggregation can lead to:

• Settling and caking, making the product hard to shake and re-suspend
• Variation in dose with each use
• Increased risk of dosing errors or sub-therapeutic effects
• Regulatory concerns over stability, performance, and patient safety

Neglecting to monitor these changes compromises both product performance and compliance with global expectations for suspension dosage forms.

Regulatory and Technical Context:

ICH and WHO expectations for suspension stability:

ICH Q1A(R2) and WHO TRS 1010 mandate monitoring of both chemical and physical parameters during stability studies. For suspensions, this includes sedimentation behavior, redispersibility, and appearance. Regulatory authorities expect that companies evaluate and document any physical instability that might compromise dose uniformity, particularly for pediatric, oral, or ophthalmic suspensions. CTD Module 3.2.P.8.3 must include references to physical stability data.

Audit readiness and quality risk management:

Regulators and auditors often assess whether physical characteristics like viscosity, particle size, and sediment volume are tracked across stability time points. Failure to evaluate these parameters may trigger audit observations or necessitate product recalls. Proper control of aggregation and crystal growth is especially important for products with narrow therapeutic windows or variable patient compliance.

Best Practices and Implementation:

Use quantitative and qualitative methods to monitor physical stability:

Incorporate the following into your stability protocol:

• Microscopic analysis to detect changes in crystal morphology
• Laser diffraction or dynamic light scattering for particle size distribution
• Visual inspection and sedimentation volume ratio (SVR)
• Redispersibility testing—standardized inversion or mechanical shaking protocols

Evaluate data at key intervals (e.g., 0M, 3M, 6M, 12M) under ICH long-term and accelerated conditions.

Establish clear acceptance criteria and reference data:

Define limits for:

• Maximum allowable particle growth (e.g., < 10% increase in D90)
• Acceptable redispersion time (e.g., < 30 seconds with 10 inversions)
• Visual appearance (no caking, no excessive sediment layer)

Compare results against freshly prepared samples to ensure consistency and stability over time.

Investigate and document any observed changes:

Any increase in particle size or aggregation during stability should trigger:

• Root cause analysis to determine mechanism (e.g., Ostwald ripening, pH drift)
• Review of excipient composition or manufacturing process
• Risk assessment for shelf-life and regulatory filing impact

Document findings in your stability summary and reflect conclusions in the final CTD submission.

Evaluating crystal growth and aggregation in suspensions isn’t optional—it’s critical for ensuring dose uniformity, therapeutic effectiveness, and regulatory trust throughout the product lifecycle.

Why aerosol performance must be part of stability testing:

Inhalation products such as pressurized metered-dose inhalers (pMDIs), dry powder inhalers (DPIs), and nebulizer solutions are highly dependent on device functionality and aerosol characteristics. The therapeutic effect is governed by the accurate delivery of a defined particle size to the lungs. Over time, physical or chemical changes in the formulation, valve integrity, or propellant loss can affect aerosol behavior. Including aerosol performance in your stability protocol ensures the inhaler’s clinical performance remains within specifications over time.

What can go wrong without performance testing:

Failure to monitor aerosol properties during stability may result in:

• Inaccurate delivered dose (DDU)
• Shift in fine particle fraction (FPF) or mass median aerodynamic diameter (MMAD)
• Loss of actuator spray pattern or plume geometry
• Device malfunction under high or low humidity conditions

These issues directly affect the product’s bioavailability and safety, especially in critical care settings like asthma, COPD, or cystic fibrosis treatment.

Regulatory and Technical Context:

Guidelines for inhalation stability from ICH and WHO:

ICH Q1A(R2) and WHO TRS 1010 mandate stability testing of inhalation products under conditions simulating long-term and accelerated storage. For orally inhaled and nasal drug products (OINDPs), regulatory agencies such as the US FDA, EMA, and MHRA expect inclusion of device-drug combination performance metrics. The CTD Module 3.2.P.8.3 must include data demonstrating consistent delivered dose and aerodynamic profile throughout the claimed shelf life.

Regulatory audit and filing expectations:

Auditors often request aerosol performance data across time points, especially if post-marketing complaints involve dose delivery issues or device failure. Missing or inconsistent data may trigger product recalls, shelf life reduction, or regulatory delays. Agencies expect validated methods for DDU and APSD (e.g., using NGI or Andersen cascade impactors), with trend analysis that confirms dose and particle size reproducibility.

Best Practices and Implementation:

Incorporate performance metrics in stability protocols:

For each time point (e.g., 0, 3, 6, 9, 12, 24 months), test:

• Delivered dose uniformity (DDU)
• Aerodynamic particle size distribution (APSD)
• Spray pattern and plume geometry (where applicable)
• Priming and tail-off performance

Store samples under ICH-recommended conditions (e.g., 25°C/60% RH, 30°C/75% RH) and evaluate any interaction between formulation and device materials (e.g., valve rubber, metal canisters).

Use validated equipment and trained operators:

Perform aerosol tests using calibrated cascade impactors (e.g., NGI), flow controllers, and dose collection apparatus. Operators must be trained in actuation technique, shaking, and sample handling to minimize variability. Ensure all tests follow approved SOPs aligned with regulatory guidance such as the FDA’s MDI/DPI draft guidance or EMA’s OINDP guideline.

Analyze and trend performance data across time points:

Use control charts and statistical trending to monitor:

• DDU within ±15% of labeled claim
• MMAD stability (within ±0.5 µm if specified)
• Consistent FPF and total emitted dose

Investigate any shift beyond control limits and document root cause assessments. Highlight these trends in the final stability summary and include supportive conclusions in CTD Module 3.2.P.8.3.

Inhalation products are only as effective as the aerosol they deliver. Ensuring consistent performance through stability testing not only protects patients—but also demonstrates product robustness, lifecycle control, and a scientifically sound regulatory strategy.

Why dose uniformity is essential in inhalation products:

Metered Dose Inhalers (MDIs) and Dry Powder Inhalers (DPIs) are used to deliver highly specific microgram-level doses to the lungs. Slight variations in dose delivery over time can lead to underdosing or overdosing, resulting in therapeutic failure or adverse effects. Stability studies must evaluate whether the device consistently delivers the labeled dose from the first to the last actuation throughout the product’s shelf life.

Impact of poor uniformity on patient safety and compliance:

If dose delivery becomes inconsistent due to valve sticking, powder aggregation, moisture uptake, or propellant degradation, it undermines both clinical effectiveness and patient trust. Pediatric, geriatric, and asthmatic populations are particularly vulnerable. Including dose uniformity in your stability protocol ensures that delivered doses remain within pharmacopeial limits across storage conditions and time points.

Regulatory and Technical Context:

ICH and pharmacopeial guidelines:

ICH Q1A(R2) and ICH Q4B recommend that the critical performance attributes of a drug delivery system be evaluated under stability conditions. USP and Ph. Eur. 2.9.18 outline the requirements for dose uniformity testing in inhalation products. These include delivered dose uniformity, valve/actuator function, and minimum delivered dose consistency throughout the container’s life cycle.

EMA and FDA guidance documents require inclusion of dose uniformity performance data under ICH long-term and accelerated conditions for regulatory approval of MDIs and DPIs.

Audit risks and regulatory submissions:

Regulatory reviewers scrutinize inhalation product stability reports for consistency in device function and dose delivery. Missing dose uniformity data may lead to clinical relevance concerns or product rejection. It also increases the likelihood of post-marketing surveillance flags or patient complaints regarding dose inconsistency.

Best Practices and Implementation:

Design time-point dose delivery assessments:

At each scheduled stability pull (e.g., 0, 3, 6, 9, 12, 24 months), test dose uniformity using at least 10 actuations from different units of the same batch. Ensure measurements are made at beginning, middle, and end of the canister life. Conduct testing under both long-term and accelerated storage conditions to simulate worst-case variability.

Record delivered dose results, actuation force consistency, plume geometry, and device integrity.

Control environmental factors influencing dose consistency:

Moisture, temperature, and mechanical wear can all affect powder flowability in DPIs or propellant behavior in MDIs. Use humidity-controlled chambers and real-use simulation tools to track changes in spray pattern, content uniformity, and aerodynamic particle size distribution. Compare results across packaging configurations (e.g., foil overwrap, plastic shell) for robustness validation.

Integrate results with product labeling and lifecycle strategy:

Link dose uniformity outcomes to the justification of shelf life and usage instructions. If variability is observed after multiple actuations, consider recommending shake-before-use instructions or specifying use within X days after opening. Include findings in CTD Modules 3.2.P.5.1 (Control of Critical Product Characteristics) and 3.2.P.8.3 (Stability Data).

Track field complaints or deviations related to inhaler performance and use this data to update SOPs, CAPA actions, and training modules for manufacturing and QA teams.